Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

NORTH Study: Panobinostat for Pediatric and Young Adult Patients with Solid Tumors - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out how an experimental drug called panobinostat works in your body and against your tumor.

What is the Condition Being Studied?

NORTH Study: Panobinostat for Pediatric and Young Adults Patients with Solid Tumors

Who Can Participate in the Study?

People younger than 40 years old who:
- Have new or recurrent ATRT or MRT
- Are recovered from side effects of past treatments, if any
- Have not used medicine that affects the immune system within the last 3 weeks

For more information about who can be in this study, please contact the study team.

Age Group
Adults, Children

What is Involved?

If you choose to join this study, you will:
- Take the study drug by mouth according to a study calendar for up to 12 months.
- Have physical exams every week for the first month and then monthly while taking the study drug
- Have blood draws and urine tests every week for the first month and then monthly while taking the study drug
- Have heart scans done (ECGs and echocardiograms)
- Have imaging scans (PET, MRI, CT, X-ray, or ultrasound) based on your type of tumor

You will return to the Duke clinic every 6 weeks for 3 months and then every 3 months for up to 2 years after you stop taking Panobinostat.

Study Details

Full Title
A Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma
Principal Investigator
Protocol Number
IRB: PRO00107447
NCT: NCT04897880
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment Soon
More Information
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698